.sg-noscript { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif; max-width: 860px; margin: 40px auto; padding: 0 24px; color: #141414; line-height: 1.6; } .sg-noscript h1 { font-size: 1.8rem; margin-bottom: 0.25rem; } .sg-noscript h2 { font-size: 1.2rem; margin-top: 2rem; margin-bottom: 0.5rem; border-bottom: 1px solid #e0e0e0; padding-bottom: 0.25rem; } .sg-noscript ul { padding-left: 1.5rem; } .sg-noscript li { margin-bottom: 0.4rem; } .sg-noscript a { color: #1a6fa8; } .sg-noscript address { font-style: normal; } .sg-noscript .note { margin-top: 2rem; color: #666; font-size: 0.85rem; }

Agora — Alzheimer's Disease Gene Evidence Portal

Agora is a publicly accessible data portal developed and maintained by Sage Bionetworks, a 501(c)(3) nonprofit biomedical research organization, with funding from the National Institute on Aging (NIA). Agora is part of the broader AD Knowledge Portal ecosystem at adknowledgeportal.org.

About Agora

Agora hosts high-dimensional human transcriptomic, proteomic, and metabolomic evidence for whether or not genes are associated with Alzheimer's disease (AD). It also contains a list of over 950 nascent AD drug targets nominated by researchers from the National Institute on Aging's Accelerating Medicines Partnership in Alzheimer's Disease (AMP-AD) consortium, the Target Enablement to Accelerate Therapy Development for Alzheimer's Disease (TREAT-AD) centers, and other research teams.

Evidence presented in Agora was generated by AMP-AD and TREAT-AD research teams or aggregated from publicly available data sources. Agora was initially developed by the NIA-funded AMP-AD consortium to share evidence in support of AD target discovery.

About the AD Knowledge Portal

The AD Knowledge Portal (adknowledgeportal.org) is an open-access database developed by Sage Bionetworks that disseminates data, tools, and analytical results generated by multiple National Institute on Aging-funded programs focused on aging, dementia, and Alzheimer's disease. The portal hosts data and resources generated across 100+ grant projects in 10+ NIA-supported programs and centers, including multi-omic data from human samples and experimental model systems.

The portal was developed as part of the Accelerating Medicines Partnership in Alzheimer's Disease (AMP-AD) program between the NIH and several nonprofit organizations and pharmaceutical companies, and has since expanded to include data from additional NIA-funded consortia.

What You Can Do on Agora

Explore transcriptomic, proteomic, and metabolomic evidence for the role of specific genes in Alzheimer's disease.
Compare differential RNA and protein expression results for 20,000+ human genes in AD.
Browse over 950 nominated AD drug targets contributed by leading research consortia.
Browse over 65 repurposable or repositionable candidate drugs that research teams have nominated as potential therapies for AD treatment or prevention.
Search for genes by name or Ensembl gene ID to view experimental evidence and nomination details.
Explore data generated by AMP-AD, TREAT-AD, and other NIA-funded research teams.

Nonprofit Identity

Sage Bionetworks
A 501(c)(3) nonprofit research organization
EIN: 26-4489946
Seattle, Washington, USA
sagebionetworks.org
Trust Center — Terms of Service, Privacy Policy, financial statements, and governance documents

Learn More

About Agora
Agora Resources documentation
AD Knowledge Portal — data, tools, and results for AD research
About the AD Knowledge Portal
Sage Bionetworks — Mission, vision, and current work
Sage Bionetworks Trust Center — financial statements, policies, and governance documents
IRS Form 990 filings (via ProPublica Nonprofit Explorer)
Contact the Agora team — agora@sagebionetworks.org

This static content is provided for search engines and users with JavaScript disabled. For the full Agora experience, please enable JavaScript in your browser.